Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Grashnov, Emil
NCT04072354 / 2019-000470-36: A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia	Completed	3	463	Europe, US, RoW	SEP-363856 50mg, SEP-363856 75mg, Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc.	Schizophrenia	05/23	09/23
NCT04092686 / 2019-000697-37: A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia	Completed	3	464	Europe, US, RoW	SEP-363856 75mg, SEP-363856 100mg, Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc.	Schizophrenia	06/23	06/23
NCT05169710 / 2021-002126-24: A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.	Terminated	3	83	Europe, Canada, Japan, US	SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo	Sumitomo Pharma America, Inc., Sunovion Pharmaceuticals Inc.	Depressive Episodes, Bipolar I Depression	10/23	10/23
NCT05729373: A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder	Recruiting	2/3	434	Europe, Japan, US	SEP-363856, Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc.	Generalized Anxiety Disorder	02/25	02/25